Detalhe da pesquisa
1.
Bispecific Complement Engagers for Targeted Complement Activation.
J Immunol
; 211(3): 403-413, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37350633
2.
Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALL.
Blood
; 140(1): 45-57, 2022 07 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35452517
3.
Unrelated or haploidentical allogeneic hematopoietic cell transplantation in second complete remission for acute myeloid leukemia-Improved outcomes over time: A European Society for Blood and Marrow Transplantation Acute Leukemia Working Party study.
Cancer
; 129(17): 2645-2654, 2023 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37269074
4.
Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET.
J Biol Chem
; 296: 100641, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33839159
5.
Enhancement of epidermal growth factor receptor antibody tumor immunotherapy by glutaminyl cyclase inhibition to interfere with CD47/signal regulatory protein alpha interactions.
Cancer Sci
; 112(8): 3029-3040, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-34058788
6.
Fc-engineering significantly improves the recruitment of immune effector cells by anti-ICAM-1 antibody MSH-TP15 for myeloma therapy.
Haematologica
; 106(7): 1857-1866, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32499243
7.
An Fc-engineered CD19 antibody eradicates MRD in patient-derived MLL-rearranged acute lymphoblastic leukemia xenografts.
Blood
; 130(13): 1543-1552, 2017 09 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-28698205
8.
Monoclonal Antibodies against Epidermal Growth Factor Receptor Acquire an Ability To Kill Tumor Cells through Complement Activation by Mutations That Selectively Facilitate the Hexamerization of IgG on Opsonized Cells.
J Immunol
; 198(4): 1585-1594, 2017 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28062698
9.
New insights in Type I and II CD20 antibody mechanisms-of-action with a panel of novel CD20 antibodies.
Br J Haematol
; 180(6): 808-820, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29468712
10.
Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells.
J Immunol
; 197(12): 4829-4837, 2016 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27807190
11.
CD47 Blockade and Rituximab in Non-Hodgkin's Lymphoma.
N Engl J Med
; 380(5): 496-7, 2019 01 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-30702240
12.
A Complement-Optimized EGFR Antibody Improves Cytotoxic Functions of Polymorphonuclear Cells against Tumor Cells.
J Immunol
; 195(10): 5077-87, 2015 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26475927
13.
Antibody Isotypes for Tumor Immunotherapy.
Transfus Med Hemother
; 44(5): 320-326, 2017 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-29070977
14.
An Fc Double-Engineered CD20 Antibody with Enhanced Ability to Trigger Complement-Dependent Cytotoxicity and Antibody-Dependent Cell-Mediated Cytotoxicity.
Transfus Med Hemother
; 44(5): 292-300, 2017 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-29070974
15.
Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia.
Blood
; 134(8): 713-716, 2019 08 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-31311816
16.
Epidermal growth factor receptor targeting IgG3 triggers complement-mediated lysis of decay-accelerating factor expressing tumor cells through the alternative pathway amplification loop.
J Immunol
; 193(3): 1485-95, 2014 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24973443
17.
Complement in antibody-based tumor therapy.
Crit Rev Immunol
; 34(3): 199-214, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24941073
18.
Boosting ADCC and CDC activity by Fc engineering and evaluation of antibody effector functions.
Methods
; 65(1): 105-13, 2014 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23851282
19.
Impact of epidermal growth factor receptor (EGFR) cell surface expression levels on effector mechanisms of EGFR antibodies.
J Immunol
; 189(11): 5230-9, 2012 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23100515
20.
Mimicking an induced self phenotype by coating lymphomas with the NKp30 ligand B7-H6 promotes NK cell cytotoxicity.
J Immunol
; 189(10): 5037-46, 2012 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23066150